Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Mitsubishi Tanabe Pharma Corporation: PharmaVitae Profile
Market Study
Published: June 2010
Pages: 64
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 3562.50 Buy Now!
Research from: Datamonitor
Sector: Corporate & Fiscal
Introduction
This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the Rx drug sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark Mitsubishi Tanabe's performance against key rivals in the prescription pharmaceutical sector
*Assess how the merger of Mitsubishi and Tanabe has provided scale, re-focused the company's strategic priorities and resource capabilities
*Assess how Mitsubishi Tanabe's launch portfolio is forecast to offset the sluggish sales growth of its aging marketed portfolio
This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the Rx drug sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark Mitsubishi Tanabe's performance against key rivals in the prescription pharmaceutical sector
*Assess how the merger of Mitsubishi and Tanabe has provided scale, re-focused the company's strategic priorities and resource capabilities
*Assess how Mitsubishi Tanabe's launch portfolio is forecast to offset the sluggish sales growth of its aging marketed portfolio